-
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 12:00 GMT
… cancer and viral infection treatments, announces today that … MedInvest Biotech & Pharma Investor Conference. The conference … carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard … product candidates during clinical development; our ability to …
-
FDA Declines Approval for Regeneron’s Blood Cancer Therapy
27 Mar 2024 03:16 GMT
… Pharmaceuticals announced on Monday that the U.S. FDA … efficacy, safety, trial design, labeling, or … non-Hodgkin lymphoma.
This setback marks the first time that the FDA … treatments before granting approval, reflecting the evolving landscape of drug development …
-
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and DLBCL
26 Mar 2024 20:35 GMT
… press release from Regeneron Pharmaceuticals, the developers of the agent. … its OLYMPIA program. The FDA required that these trials … open-label ELM-2 trial evaluated treatment with odronextamab in … , and other B-cell non-Hodgkin lymphoma subtypes.
The primary …
-
Arovella Therapeutics to raise funds for trial of lymphoma drug
26 Mar 2024 13:59 GMT
… indicated for the treatment of CD19-positive non-Hodgkin’s lymphoma.
… required for filing investigational new drug (IND) applications.
Arovella … for a Phase I trial of the cell therapy. … develop a chimeric antigen receptor iNKT (CAR-iNKT) cell therapy to treat …
-
Edgewood secures $20m in Series A for clinical development of cancer therapy
26 Mar 2024 13:59 GMT
… majority of drugs in development being enzyme inhibitors, according to GlobalData Pharma Intelligence … a treatment for solid tumours and non-Hodgkin lymphoma, open-label Phase I trial … from the US Food and Drug Administration (FDA). A month later, Sellas …
-
Peripheral T-cell Lymphoma Market to Witness Growth by 2034, Estimates DelveInsight
28 Mar 2024 12:30 GMT
… report provides current treatment practices, emerging drugs, the market share … 2023, Innate Pharma announced that the US FDA has placed … a possible Phase II registrational trial.
• In December 2023, … types of non-Hodgkin lymphoma (NHL) that develop in mature …
-
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
28 Mar 2024 13:00 GMT
… cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development … cures for difficult-to-treat cancers and rare genetic … clinical trial to evaluate MB-106 for the treatment of … cures for difficult-to-treat cancers and rare genetic …
-
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL
26 Mar 2024 00:40 GMT
… common non-Hodgkin lymphoma subtypes—was accepted for FDA priority … the treatment paradigm of several B-cell non-Hodgkin lymphoma … agent granted orphan drug designation in the European … phase 2 trial. News release. Regeneron Pharmaceuticals. December 12 …
-
Health Beat: New hope for Non-Hodgkin’s Lymphoma patients
25 Mar 2024 22:01 GMT
… of Non-Hodgkin’s lymphoma. Now, the FDA has approved a new treatment for … the end. Then, a new trial led by a City of … .”
In the trial, 80 percent of patients responded to treatment, 60 percent … or in combination with other medications.
-
FDA turns down Regeneron bispecific blood cancer antibody
25 Mar 2024 16:23 GMT
… antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL).
… be the broadest of any drug in the class.
The … the FDA states that it “strongly recommends that the confirmatory trial(s … expand the label for their drugs in other forms of NHL …